✨ Free AI Report
Travere Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Travere Therapeutics, Inc.
Company Research

Travere Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Travere Therapeutics, Inc., a biopharmaceutical company, is dedicated to identifying, developing, and delivering life-changing therapies to individuals with rare diseases. With a focused mission to...

Analyst-debate audio for Travere Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Travere Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Company OverviewProduct PortfolioLeadership and Management TeamFinancial Overview of Travere Therapeutics, Inc.Marketing StrategiesTravere Therapeutics, Inc. Market Research and Competitors
Get Interactive Report Freeor start reading below
Live on AskCyborg
8/10Strong
Travere Therapeutics, Inc.

Rare kidney disease specialist with accelerating FILSPARI adoption, strong cash position, near-term FSGS approval catalyst, and meaningful clinical pipeline expansion opportunity.

▶︎ Listen to the 90-second analyst debate
8/ 10Strong

Cyborg Score thesis

Rare kidney disease specialist with accelerating FILSPARI adoption, strong cash position, near-term FSGS approval catalyst, and...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Rare Kidney and Metabolic Diseases
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: August 24, 2026
AI-Verified Research
30+ Page Report

Get the Latest Travere Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Travere Therapeutics, Inc., a biopharmaceutical company, is dedicated to identifying, developing, and delivering life-changing therapies to individuals with rare diseases. With a focused mission to make a meaningful impact on patients’ lives, Travere Therapeutics has established itself as a key player in the biotech industry.

Company Overview

Pro stress-test →

Travere Therapeutics, Inc., formerly known as Retrophin, Inc., was founded in 2011. Headquartered in San Diego, California, the company specializes in developing innovative therapies for patients with rare diseases. Travere Therapeutics leverages its deep understanding of rare diseases to address unmet medical needs and improve patient outcomes.

Product Portfolio

Pro stress-test →

Travere Therapeutics’ product portfolio includes a range of therapies targeting rare diseases. Key products include:

  • Chenodal®: A bile acid therapy used for treating cerebrotendinous xanthomatosis (CTX).
  • Thiola®: A therapy aimed at treating cystinuria, a rare inherited disorder.
  • Sparsentan: An investigational product for treating focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).

Leadership and Management Team

Pro stress-test →

Travere Therapeutics boasts a strong leadership team dedicated to advancing the company’s mission. Key members include:

  • Eric Dube, Ph.D.: President and Chief Executive Officer
  • Peter Heerma: Chief Commercial Officer
  • Noel Donnelly: Chief Financial Officer

Financial Overview of Travere Therapeutics, Inc.

Travere Therapeutics, Inc. has demonstrated strong financial performance with significant investments in research and development. The company’s revenue is primarily driven by its commercial products, with a keen focus on expanding its pipeline of innovative therapies. Key financial metrics include:

  • Annual Revenue: $200 million (approx.)
  • R&D Investment: Over $100 million annually
  • Market Capitalization: $1.5 billion (approx.)

Marketing Strategies

Travere Therapeutics employs a multi-faceted marketing strategy to increase brand awareness and drive the adoption of its therapies. Key strategies include:

  • Engaging with healthcare professionals through targeted medical education initiatives.
  • Leveraging digital marketing platforms to reach a broader audience.
  • Participating in industry conferences and events to showcase their latest innovations.

Travere Therapeutics, Inc. Market Research and Competitors

The rare disease market is highly competitive, with several key players striving to develop breakthrough therapies. Travere Therapeutics, Inc. stands out due to its focused approach and strong pipeline. Main competitors include:

  • Alexion Pharmaceuticals
  • BioMarin Pharmaceutical
  • Ultragenyx Pharmaceutical

Sales Strategies

Travere Therapeutics utilizes a comprehensive sales strategy to effectively reach its target market. The company employs a specialized sales force with deep expertise in rare diseases and leverages strong relationships with key opinion leaders and healthcare providers. Sales channels include direct sales, partnerships, and collaborations with healthcare institutions.

Technologies Utilized

Travere Therapeutics leverages cutting-edge technologies and innovative approaches to advance its research and development efforts. Key technologies include:

  • Advanced genomic and proteomic analysis.
  • State-of-the-art biopharmaceutical manufacturing processes.
  • Robust data analytics and bioinformatics platforms.

HR Practices

Travere Therapeutics places a strong emphasis on fostering a collaborative and inclusive work environment. Key HR practices include:

  • Offering comprehensive employee development programs.
  • Promoting diversity and inclusion across all levels of the organization.
  • Providing competitive compensation and benefits packages.

Corporate Responsibility

Travere Therapeutics is committed to corporate social responsibility and making a positive impact on society. Key initiatives include:

  • Supporting patient advocacy organizations and community programs.
  • Implementing sustainable and environmentally friendly practices.
  • Engaging in philanthropic activities and volunteerism.

Future Plans

Looking ahead, Travere Therapeutics aims to continue expanding its pipeline of innovative therapies and advancing its clinical programs. The company is focused on:

  • Bringing new treatments to market for additional rare diseases.
  • Exploring strategic partnerships and collaborations.
  • Enhancing its global presence and market reach.

Get the full report on Travere Therapeutics, Inc. by subscribing now!


What the analysts stress-tested

The top findings that survived the multi-agent debate for Travere Therapeutics, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Travere Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

FSGS and IgAN treatmentsDeveloping therapies for kidney diseaseCystinuria treatmentRare disease biopharmaceuticalRare kidney disease focusLupus nephritis and other kidney disorders

Compare Travere Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Travere Therapeutics, Inc. operates in Biopharmaceutical - Rare Kidney and Metabolic Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Rare Kidney and Metabolic Diseases research →
NEW · MCP server

Ask your AI assistant about Travere Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Travere Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Travere Therapeutics, Inc. do this quarter?”
“Is Travere Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Travere Therapeutics, Inc. do?+
Travere Therapeutics, Inc., a biopharmaceutical company, is dedicated to identifying, developing, and delivering life-changing therapies to individuals with rare diseases. With a focused mission to...
What is Travere Therapeutics, Inc.'s Cyborg Score?+
Travere Therapeutics, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Travere Therapeutics, Inc.'s main competitors?+
Named competitors include FSGS and IgAN treatments, Cystinuria treatment, Rare kidney disease focus. The full competitive landscape is in the AskCyborg report.
How can I get the full Travere Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Travere Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Travere Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Company Research

Gambling and Lotteries Industry BriefingStationery and Office Products Industry BriefingDefense Tech Industry BriefingAi Infrastructure Systems Industry BriefingPet Insurance Industry BriefingSelf-Storage Industry BriefingMetal Additive Manufacturing Industry BriefingAi Accelerator Hardware Systems Industry BriefingLuxury Wines & Spirits Industry BriefingEnzymatic Plastic Recycling Industry BriefingInfrastructure as a Service (IaaS) Industry Briefingluxury fashion apparel Industry Briefing

Explore Industry Research

Travel Insurance Industry Company Research ReportSecurity Services Industry Company Research ReportLandscaping and Grounds Maintenance Industry Company Research ReportJanitorial and Cleaning Services Industry Company Research ReportSustainability Consulting Industry Company Research ReportReal Estate Investment Trusts (REITs) Industry Company Research Report
Browse All Company ResearchBrowse All Industry ResearchRSS Feed